
doi: 10.5414/cpp47063
pmid: 20040314
Enzyme replacement therapy (ERT) is now available for several of the mucopolysaccharidosis disorders. This brief review summarizes the role of ERT in reducing the burden of peripheral disease in many patients with mucopolysaccharidosis disorders, and describes the challenges that remain in treating the neurological manifestations of these conditions.
Mucopolysaccharidosis VI, N-Acetylgalactosamine-4-Sulfatase, Mucopolysaccharidosis I, Hematopoietic Stem Cell Transplantation, Iduronate Sulfatase, Combined Modality Therapy, Recombinant Proteins, Iduronidase, Enzyme replacement therapy, Hematopoietic stem cell therapy, Palliative care, Humans, Surgery, Enzyme Replacement Therapy, Mucopolysaccharidosis disorders, Mucopolysaccharidosis II
Mucopolysaccharidosis VI, N-Acetylgalactosamine-4-Sulfatase, Mucopolysaccharidosis I, Hematopoietic Stem Cell Transplantation, Iduronate Sulfatase, Combined Modality Therapy, Recombinant Proteins, Iduronidase, Enzyme replacement therapy, Hematopoietic stem cell therapy, Palliative care, Humans, Surgery, Enzyme Replacement Therapy, Mucopolysaccharidosis disorders, Mucopolysaccharidosis II
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 23 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
